Washington. American drugmakers Pfizer and BioNTech have sought permission from the US drugs regulator Food and Drug Administration for emergency use of the corona vaccine for children aged 5 to 11 years. With this step, about 28 million children of America will be able to get protection from the vaccine. Pfizer said that data in support of this has been submitted to the FDA on their behalf. On the request of the pharmaceutical company, a meeting has been scheduled on October 26, taking immediate steps from the drugs regulator.
Parents in the US are eagerly waiting for the regulators’ decision, which could have a positive impact on their family life and the operation of schools. Its approval depends not only on clinic data, but they also have to make sure they can prove to regulators that they are capable of properly manufacturing a new pediatric formulation.
WHO approves world’s first malaria vaccine, every 2 minutes a child dies
Prior to this, the UK had provided Pfizer to all children aged 12 to 15. One dose of BioNTech’s Kovid-19 vaccine has been approved. Most of the vaccines are being administered in schools. Schools are also helping to provide vaccine doses to children, including through a consent process. Parental approval is required to administer the vaccine to children under 16 years of age.
Experts say that children between 12 and 18 years should be vaccinated first, because they are at a higher risk of corona infection in terms of age. Second, if children of this age are suffering from any disease then they are at higher risk. Not only this, experts also say that before starting the vaccination of children, the government should make a separate protocol, so that taking care of these things, from the parents to the vaccination team, are involved in the vaccination.
Double vaccine gives 94% protection after corona infection – British study
Preparation for vaccination of children in India too
In the next few days, corona vaccination of children below 18 years of age can also start in India. The study of covaccine on children aged 2 to 18 years is almost complete. Final report is coming. Early signs are said to be good. The results of the vaccine in adults so far have been seen that infection is occurring even after the vaccine, but the disease is decreasing, hospital admission is decreasing and due to this the death is also decreasing. Therefore, it would be better if the vaccine is administered earlier in children of 12 to 18 years and already sick children. (with agency input)